Αποτελέσματα Αναζήτησης
5 Ιαν 2012 · The HSV vaccine was associated with an increased risk of local reactions as compared with the control vaccine, and it elicited ELISA and neutralizing antibodies to HSV-2. Overall, the vaccine...
- Maternal and Neonatal Herpes Simplex Virus Infections
Whether it is caused by herpes simplex virus (HSV) type 1 or...
- NEJM
Serologic surveys indicate that the prevalence of infection...
- Maternal and Neonatal Herpes Simplex Virus Infections
3 Ιουν 2016 · As current control strategies for genital HSV-2 infection, including antiviral therapy and condom use, are only partially effective, vaccines will be required to reduce infection. Both preventive and therapeutic vaccines for HSV-2 are being pursued and are in various stages of development.
30 Ιαν 2017 · Genital herpes simplex virus type 2 (HSV-2) infection causes recurrent lesions and frequent viral shedding. GEN-003 is a candidate therapeutic vaccine containing HSV-2 gD2∆TMR and ICP4.2, and Matrix-M2 adjuvant.
1 Απρ 2017 · A dual-modality herpes simplex virus 2 vaccine for preventing genital herpes by using glycoprotein C and D subunit antigens to induce potent antibody responses and adenovirus vectors containing capsid and tegument proteins as T cell immunogens.
27 Ιουλ 2020 · A prophylactic herpes vaccine is needed to protect against genital infections by both HSV-1 and HSV-2. Previously our laboratory developed a trivalent vaccine that targets glycoproteins C, D, and E present on the HSV-2 virion.
Led by principal investigator Lesia K. Dropulic, M.D., of NIAID’s Laboratory of Infectious Diseases, the trial will test an investigational HSV-2 vaccine candidate, called HSV529, for safety and the ability to generate an immune system response.
A novel herpes vaccine, developed by scientists from the Perelman School of Medicine at the University of Pennsylvania, has achieved a nearly 100-percent success rate in animal testing. The...
